Any Covid-19 vaccine? All nations and the entire world humanity was eagerly awaiting the precious announcement from at least one top nation that its scientists have successfully completed clinical trials of Covid-19 vaccine.
Moderna spokesperson Ray Jordan confirmed the estimated start date to CNBC. The trial is now expected to begin July 27.
The ongoing Phase 1 trial is supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Approval: In the last stage, the vaccine developer gets approval from the authorised body.
But he cautioned that more work was needed to evaluate the vaccine's safety - including making sure that it did not backfire by eventually making the immune system "tolerant" toward the real virus.
They explained that systemic adverse events were more common following the second vaccination, and in those who received the highest vaccine dose. Experts say that the global scientific community would now vet the efficacy of the vaccine before it can be used by countries across the world.
According to the ICMR guidelines, the first dose of Covaxin will be administered only to the patients with normal health reports. Researchers reported the good news from their original data, which was taken from 45 volunteers who rolled up their sleeves in March, to serve as the initial test subjects.
NFL’s Washington to drop Redskins nickname on Monday
The decision comes 11 days after naming-rights sponsor FedEx's public statement asking for a change to the controversial moniker. This despite the name coming under increased scrutiny in recent years as being racist and demeaning toward Native Americans.
In April, the trial was expanded to enroll adults older than age 55 years; it now has 120 participants.
Researchers measured virus-recognizing antibodies in all participants and detected levels similar to or higher than those found in the blood of people who have recovered from COVID-19.
Russia's Sechenov University: Russia made headlines on Sunday after it said that the first phase of the clinical trial has proved to be successful. While the first group of volunteers will be permitted to leave in two-three days, the second group will be discharged on July 20.
In cases where there were side effects from the vaccine, most commonly participants felt fatigue, chills, headache and myalgia, all of which were transient and mild or moderate in severity, according to the news release.
The further vaccine development plan is already being determined by the developer's strategy, including the complexity of the epidemiological situation with the virus and the possibility of scaling up production, Lukashev added.
The company estimates it could deliver 500 million doses per year, starting in 2021. Shares of the company, based in Cambridge, Massachusetts, have almost quadrupled this year.
Out of the 140 companies around the world racing to produce a vaccine for COVID-19, five other Indian companies are also working on vaccine development.